Elegen Early Access Partners Receive High-Complexity, Long DNA Sequences in Rapid Time

Elegen, a leader in DNA innovation, today announced the expedited delivery of high-complexity DNA sequences longer than 15,000 base pairs to members of their exclusive early access program. The deliveries demonstrate Elegen’s commitment to continuously enhancing its DNA offering and…

Read MoreElegen Early Access Partners Receive High-Complexity, Long DNA Sequences in Rapid Time

Roquette Announces Strategic Investment and Innovation Agreement with Beren Therapeutics P.B.C.

Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential of Beren’s cyclodextrin technologies…

Read MoreRoquette Announces Strategic Investment and Innovation Agreement with Beren Therapeutics P.B.C.

Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer

Pulse Biosciences, Inc. (Nasdaq: PLSE), Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced the appointment of Gansevoort “Gan” Dunnington, M.D. as its…

Read MorePulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer

FEMSelect Breaks into U.S. Market with AcuityMD to Speed Market Access for its Minimally Invasive Women’s Health Device

BOSTON–(BUSINESS WIRE)–AcuityMD, providers of a novel commercial platform for medical technology (MedTech) companies, announces its partnership with FEMSelect, a MedTech manufacturer specializing in a minimally invasive approach to treat pelvic floor disorders (PFD). FEMSelect is leveraging AcuityMD’s platform to accelerate identification…

Read MoreFEMSelect Breaks into U.S. Market with AcuityMD to Speed Market Access for its Minimally Invasive Women’s Health Device

Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028

DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers…

Read MoreDexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028

2 Day Training Course on Advanced Regulatory Affairs for Medical Devices: October 9-10, 2023 – ResearchAndMarkets.com

The regulatory environment for medical devices is in a transitional period. With the increased focus on patient safety, the MDR has introduced many changes to the requirements and processes involved. Designed for professionals with a working knowledge of medical device…

Read More2 Day Training Course on Advanced Regulatory Affairs for Medical Devices: October 9-10, 2023 – ResearchAndMarkets.com

Thubrikar Aortic Valve to Present Promising Initial Results of CE Mark-Enabling Study With Novel Optimum TAV™ at EuroPCR 2023

Thubrikar Aortic Valve, Inc., is happy to announce that results of the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV™) in patients with severe aortic stenosis will be presented at the upcoming EuroPCR 2023 Conference. EuroPCR…

Read MoreThubrikar Aortic Valve to Present Promising Initial Results of CE Mark-Enabling Study With Novel Optimum TAV™ at EuroPCR 2023